Literature DB >> 11952318

Diffusion MR imaging in glioma: does it have any role in the pre-operation determination of grading of glioma?

W W M Lam1, W S Poon, C Metreweli.   

Abstract

AIM: To investigate the role of the diffusion MR weighted sequence in the pre-operative grading of gliomas, and its application in defining the different components of these tumours.
MATERIALS AND METHODS: Seventeen patients with gliomas (eight high grade, nine low grade) had diffusion weighted imaging. Apparent diffusion coefficients (ADCs) of different components of tumours were measured.
RESULTS: ADC of the cystic portion of the tumour was significantly higher than ADCs of the enhanced tumour, non-enhanced tumour and perifocal oedema (P < 0.01). No significant difference in ADC values between low grade and high grade glioma (P > 0.7) was found nor was there any difference between oligoglioma and non-oligoglioma (P > 0.29).
CONCLUSION: ADC value was useful to differentiate the cystic from the solid components of the tumours. However, it was not useful in pre-operative grading of glioma. Copyright 2002 The Royal College of Radiologists.

Entities:  

Mesh:

Year:  2002        PMID: 11952318     DOI: 10.1053/crad.2001.0741

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  51 in total

Review 1.  Methodology of diffusion-weighted, diffusion tensor and magnetisation transfer imaging.

Authors:  S J Price; D J Tozer; J H Gillard
Journal:  Br J Radiol       Date:  2011-12       Impact factor: 3.039

2.  Multiparametric 3T MR approach to the assessment of cerebral gliomas: tumor extent and malignancy.

Authors:  Alfonso Di Costanzo; Tommaso Scarabino; Francesca Trojsi; Giuseppe M Giannatempo; Teresa Popolizio; Domenico Catapano; Simona Bonavita; Nicola Maggialetti; Michela Tosetti; Ugo Salvolini; Vincenzo A d'Angelo; Giocchino Tedeschi
Journal:  Neuroradiology       Date:  2006-06-03       Impact factor: 2.804

3.  High b-value diffusion (b = 3000 s/mm2) MR imaging in cerebral gliomas at 3T: visual and quantitative comparisons with b = 1000 s/mm2.

Authors:  H S Seo; K-H Chang; D G Na; B J Kwon; D H Lee
Journal:  AJNR Am J Neuroradiol       Date:  2007-12-07       Impact factor: 3.825

4.  Neuroradiological assessment of newly diagnosed glioblastoma.

Authors:  Srini Mukundan; Chad Holder; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

5.  Stretched-exponential model diffusion-weighted imaging as a potential imaging marker in preoperative grading and assessment of proliferative activity of gliomas.

Authors:  Xiaowei Chen; Jingjing Jiang; Nanxi Shen; Lingyun Zhao; Jiaxuan Zhang; Yuanyuan Qin; Shun Zhang; Li Li; Wenzhen Zhu
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

Review 6.  Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies.

Authors:  Nishant Verma; Matthew C Cowperthwaite; Mark G Burnett; Mia K Markey
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

7.  Emerging techniques and technologies in brain tumor imaging.

Authors:  Benjamin M Ellingson; Martin Bendszus; A Gregory Sorensen; Whitney B Pope
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

8.  A radiomics nomogram may improve the prediction of IDH genotype for astrocytoma before surgery.

Authors:  Yan Tan; Shuai-Tong Zhang; Jing-Wei Wei; Di Dong; Xiao-Chun Wang; Guo-Qiang Yang; Jie Tian; Hui Zhang
Journal:  Eur Radiol       Date:  2019-04-10       Impact factor: 5.315

9.  Distinction between glioma progression and post-radiation change by combined physiologic MR imaging.

Authors:  Eiji Matsusue; James R Fink; Jason K Rockhill; Toshihide Ogawa; Kenneth R Maravilla
Journal:  Neuroradiology       Date:  2009-10-16       Impact factor: 2.804

10.  Diffusion-weighted imaging in the follow-up of treated high-grade gliomas: tumor recurrence versus radiation injury.

Authors:  Patrick A Hein; Clifford J Eskey; Jeffrey F Dunn; Eugen B Hug
Journal:  AJNR Am J Neuroradiol       Date:  2004-02       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.